• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

MHE State of the Industry survey: Grading the Trump Administration COVID-19 response

Publication
Article
MHE PublicationMHE December 2020
Volume 30
Issue 12

In this third of a six-part series, respondents give administration poor marks.

Most of the readers who filled out our State of the Industry survey did so before the November 3 election. A majority (53%) graded the administration’s response to the pandemic as poor (47%) or fair (6%). A sizable minority (42%) deemed it good (20%) or excellent (22%).

The respondents rated the performance of federal government officials. Fifty-two percent of Anthony Fauci’s rankings were in the excellent category. Fauci is the now-famous director of National Institute of Allergy and Infectious Diseases. Twenty-one percent of Alex Azar’s rankings were in the “poor” category. Azar is HHS secretary.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.